Growth factors—natural molecules that control stem cells—are currently injected at dangerously high doses because the body destroys them too quickly, risking tumour formation. This project engineers implantable materials that release low, steady doses of growth factors over time, solving the delivery problem. If successful, the technology could make growth factor treatments safer for bone repair, bone marrow transplants, and heart attack recovery, and allow doctors to combine them with stem cell transplants without reserving such therapies only for the most urgent cases. Reduced doses would also cut the high cost of these treatments per patient. The work is applied bioengineering, not fundamental science: the researchers have already developed the core material technology and now aim to refine it for clinical use. The impact would be a new therapeutic paradigm that unlocks the regenerative potential of growth factors and stem cells, moving beyond current approaches that fall short.
View original technical description
Growth factors are molecules within our body that participate in many physiological process that are key during development as they control stem cell function. These molecules thus have the potential to drive the regeneration of tissues in a broad range of medical conditions, including in musculoskeletal (bone repair), haematological (bone marrow transplantation) and cardiovascular (infarction, heart attack) diseases. Growth factors are currently produced commercially and are used regularly in clinical applications. However, they are very power cell signalling molecules and dose is critical as balance between effect and safety has to be considered. To date the use of growth factors in regenerative medicine has been only partially successful and even controversial. The growth factors are rapidly broken down and cleared by the body. This makes prolonged delivery (as is required to effect repair) a problem and typically higher than wanted doses are administered to get around this. While their help in regeneration is undoubted, collateral side effects can be catastrophic e.g. tumour formation. We have developed new technology that directly addresses these concerns as it uses materials (that can be topically implanted) to deliver low, but effective, growth factor doses; this programme is about the safe use of growth factors in clinical applications. This will not only reduce risks for patients who currently receive growth factor treatments, but will open up therapies that can include co-transplantation with stem cells to a wider range of patients as doctors would not have to keep these therapies back for cases of most pressing need. This increased use would minimise costs as growth factors are very expensive and reduced dose would save money per treatment. Our approach is unique and this programme grant will allow us to enhance the UK's world leading position through innovative bioengineering. We know that stem cells have huge regenerative potential and that growth factors provide exquisite stem cell control - both are currently untapped. We will engineer new materials to enable growth factor technology, and critically stem cell technologies, where traditional approaches are falling very short of the mark.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know